We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company¿s proprietary dually derived chitosan (DDX) platform has a high degree o... enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company¿s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company¿s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium. Show more
Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also announces Dr. Raj Pruthi’s promotion to Chief Medical Officer enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or...
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
Company announces plans for initial indication expansion for EG-70 into high-risk papillary-only NMIBC enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic...
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive...
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive...
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024...
/C O R R E C T I O N -- enGene Inc./ PR Newswire BOSTON and MONTREAL, April 9, 2024 In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and...
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development PR Newswire BOSTON and MONTREAL, April 9, 2024 BOSTON and MONTREAL, April 9, 2024...
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress PR Newswire BOSTON and MONTREAL, March 11, 2024 Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive...
enGene To Present at the Leerink Partners Global Biopharma Conference PR Newswire BOSTON and MONTREAL, March 5, 2024 BOSTON and MONTREAL, March 5, 2024 /PRNewswire/ - enGene Holdings Inc...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -0.221729490022 | 9.02 | 9.3 | 7.91 | 87478 | 8.85013599 | CS |
| 4 | 1.08 | 13.6363636364 | 7.92 | 9.8476 | 7.62 | 149924 | 8.95578369 | CS |
| 12 | -6.46 | -41.7852522639 | 15.46 | 16.25 | 6.91 | 121945 | 10.26525788 | CS |
| 26 | 1.7 | 23.2876712329 | 7.3 | 18.4 | 6.91 | 84845 | 12.23501519 | CS |
| 52 | -7.99 | -47.0276633314 | 16.99 | 43 | 6.69 | 74970 | 11.83832635 | CS |
| 156 | -7.99 | -47.0276633314 | 16.99 | 43 | 6.69 | 74970 | 11.83832635 | CS |
| 260 | -7.99 | -47.0276633314 | 16.99 | 43 | 6.69 | 74970 | 11.83832635 | CS |
Monksdream
3 weeks ago
jump1
8 months ago
jump1
8 months ago
dinogreeves
8 months ago
dinogreeves
8 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
